HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Growth Hormone-Secreting Pituitary Adenoma

Subscribe to New Research on Growth Hormone-Secreting Pituitary Adenoma

A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.

Also Known As:

GH-Secreting Pituitary Adenoma; Adenoma, Somatotroph; Adenomas, Somatotroph; GH Secreting Pituitary Adenoma; GH-Secreting Pituitary Adenomas; Pituitary Adenoma, GH Secreting; Pituitary Adenomas, GH-Secreting; Pituitary Growth Hormone Secreting Adenoma; Somatotroph Adenomas; Pituitary Adenoma, GH-Secreting; Pituitary Growth Hormone-Secreting Adenoma; Somatotroph Adenoma

Networked: 306 relevant articles (17 outcomes, 25 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Acromegaly
2.	Pituitary Neoplasms (Pituitary Adenoma)
3.	Adenoma (Adenomas)
4.	Carcinoid Tumor (Carcinoid)
5.	Islet Cell Adenoma (Islet Cell Tumors)

Experts

1.	Bollerslev, Jens: 7 articles (01/2015 - 04/2008)
2.	Korbonits, Márta: 6 articles (02/2016 - 09/2003)
3.	Berg, Jens Petter: 6 articles (01/2015 - 04/2008)
4.	Lekva, Tove: 6 articles (01/2015 - 05/2010)
5.	Melmed, Shlomo: 5 articles (04/2015 - 04/2003)
6.	Giustina, A: 4 articles (01/2015 - 03/2002)
7.	Heck, Ansgar: 4 articles (01/2015 - 01/2013)
8.	Ueland, Thor: 4 articles (01/2015 - 08/2012)
9.	Grossman, Ashley B: 4 articles (12/2014 - 09/2003)
10.	Barlier, Anne: 4 articles (12/2014 - 10/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Growth Hormone-Secreting Pituitary Adenoma:

1.	Growth Hormone (Somatotropin)IBA 10/01/2010 - "Using strict biochemical remission criteria, the authors assessed surgical outcomes after endoscopic transsphenoidal resection of growth hormone (GH)-secreting pituitary adenomas and identified preoperative factors that significantly influence the rate of remission. " 05/01/2009 - "We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors that significantly influence the remission. " 10/01/2010 - "The aim of this study was to determine the preoperative predictors of the extent of resection and endocrinological remission following endonasal endoscopic removal of growth hormone (GH)-secreting pituitary adenomas. " 01/01/2012 - "The resection of growth hormone-(GH-) secreting pituitary adenomas in the hands of experienced surgeons results in hormonal remission in 50-70% of patients. " 12/10/2003 - "To evaluate the efficacy of gamma knife radiosurgery (GKS) in treatment of growth hormone (GH)-secreting pituitary adenoma. "
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/01/2005 - "Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60% of cases. " 09/01/2013 - "Our study indicates that ESRP1 in somatotroph adenomas regulates transcripts that may be essential in the EMT progression and in the response to somatostatin analog treatment. " 01/01/2015 - "Patients with germline AIP mutations or low AIP protein expression have large, invasive somatotroph adenomas and poor response to somatostatin analogues (SSA). " 11/01/2014 - "Before pregnancy three women had incomplete surgical resection of GH-secreting pituitary adenoma, all were treated with somatostatin analogues, and the medical treatment was withdrawal at the diagnosis of gestation. " 07/01/2013 - "To report the rare occurrence of a patient with thyrotropinoma that transitioned into a secretory thyro-somatotroph adenoma during medical treatment with somatostatin analogue. "
3.	Octreotide (Sandostatin)FDA LinkGeneric 11/01/2013 - "We aimed to determine the expression of SSTRs 1, 2a, 3, and 5 in somatotroph adenomas, to correlate expression with clinical characteristics and the response to octreotide, and to ascertain whether preoperative octreotide treatment affected SSTR expression. " 09/01/2012 - "Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up." 02/01/2012 - "We investigated the effect of DG3173, including its relation to specific tumour characteristics, on GH secretion in human somatotroph adenoma cell cultures (hSA) in comparison with Octreotide. " 01/01/2009 - "To elucidate factors influencing the acute effect of octreotide, we collected data from 56 patients with somatotroph adenoma from two institutions. " 03/01/2005 - "Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery."
4.	lanreotide (Somatuline)FDA Link 04/01/2003 - "A short administration of preoperative lanreotide 30 mg induced a statistically significant shrinkage of GH-secreting pituitary adenomas where this reduction was > 20% of the pretreatment value in 29% of the whole population. " 04/01/2003 - "Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage." 12/01/2004 - "Recent studies in molecular pathogenesis aiming to find novel therapy targets and reports on new pharmacological drugs effecting GH-secreting pituitary adenomas are reviewed (for example, lanreotide 60, SOM320 and pegvisomant). " 07/01/2003 - "This study was aimed to characterize the intracellular mechanisms mediating the in vitro antiproliferative and antisecretory effects of somatostatin and its analogue lanreotide, on primary cultures of GH-secreting pituitary adenoma cells. " 01/01/1994 - "RC-160 significantly inhibited GH-, PRL, and/or alpha-subunit release by human GH-secreting pituitary adenoma cells in concentrations as low as 10(-12)-10(-14) M, whereas at the same concentrations, octreotide and BIM-23014 did not inhibit or were significantly less effective in inhibiting GH release (P < 0.01, RC-160 vs. octreotide and BIM-23014). "
5.	ProlactinIBA 10/01/2005 - "We investigated DA subtype 2 receptor (DR2) and SRIF receptor (sst) subtypes 2 and 5 expression in 25 GH-secreting pituitary adenomas and tested in primary culture the effects on GH and prolactin (PRL) secretion of sst agonists selectively interacting with sst2 (BIM-23120), sst5 (BIM-23206), and sst2 and sst5 (BIM-23244). " 01/01/2013 - "Pituitary histopathologic findings revealed pure GH-producing somatotroph adenomas (SA) in 147 patients, prolactin-production by mixed lactotroph (LA) and SA or mammosomatotroph adenoma (MSA) in 46 [22.4%], acidophil stem cell adenoma in 6 [2.9%], and other diagnoses in 6 [2.9%]. " 03/01/1979 - "Amongst the latter are included somatotroph adenomas, prolactin cell adenomas, melanocorticotroph adenomas and thyrotroph adenomas. " 01/01/2010 - "Double pituitary adenomas are rare occurrences in autoptical, surgical and neuroradiological series and are mostly due to non-functioning pituitary adenomas, GH-secreting and prolactin-secreting adenomas. " 04/24/2004 - "In three patients gynaecomastia was diagnosed: a 22-year-old man with concomitant thyrotoxicosis due to an extensively metastasized extragonadal choriocarcinoma, a 53-year-old man with hypogonadism due to Klinefelter's syndrome that was biochemically obscured due to medications leading to elevated prolactin levels, and a 62-year-old man with acromegaly and secondary hypogonadism due to a mixed prolactin and growth hormone secreting pituitary adenoma. "
6.	Adrenocorticotropic Hormone (ACTH)FDA Link 09/01/2001 - "The hyperplastic and adenomatous ACTH-immunoreactive cells were admixed with somatotroph adenoma cells. " 01/01/1996 - "There have been, to our knowledge, only five published reports on somatotroph adenomas accompanied by excessive ACTH secretion. " 01/01/1996 - "However, somatotroph adenomas showing hypersecretion of adrenocorticotropic hormone (ACTH) are extremely rare. " 01/01/2001 - "A marked decrease of p27 expression was noted in ACTH-secreting adenomas, 8/20 (40.0%), compared with other types of pituitary adenomas--GH-secreting adenomas, 35/46 (76.1%); PRL-secreting adenomas, 22/33 (66.7%); TSH-secreting adenomas, 8/11 (72.7%); and nonfunctioning adenomas, 55/69 (79.7%). " 11/01/2001 - "Silent mixed corticotroph and somatotroph adenomas are characterized by the following: no endocrine symptoms; presentation dominated by mass effect symptoms; macroadenoma presenting with acute pituitary hemorrhage; and production of both ACTH and GH."
7.	Glucose (Dextrose)FDA LinkGeneric 01/01/2013 - "Patients with pure somatotroph adenomas are more likely than those with mixed adenomas to exhibit abnormal glucose metabolism." 01/01/2013 - "Importantly, patients with pure somatotroph adenomas were significantly more likely to present with abnormal glucose metabolism [48.7%] than those with mixed adenomas [9.7%] [p<0.001] independent of GH/IGF-1 levels or tumor invasiveness. " 12/01/2002 - "The suppression of growth hormone (GH) to less than 1 microg/L during the oral glucose tolerance test (OGTT) is generally considered to be the standard for the assessment of biochemical remission of GH excess following surgery for GH-secreting pituitary adenomas. " 10/01/2004 - "Subjects with somatotroph adenoma presented with classical features of acromegaly: mean fasting and post glucose suppression growth hormone levels were 34.04+/-11.67 and 36.47+/-6.64 ng/ml. Eleven subjects (9 females and 2 males) had prolactinoma; females presented with the classical symptom complex of amenorrhea-galactorrhea while males presented with headache, visual disturbances and impotence. " 05/01/2002 - "The objective of this study was to investigate the relationship between growth hormone (GH) dynamic tests (thyrotropin-releasing hormone [TRH] test and oral glucose tolerance test [OGTT]), insulin-like growth factor-I (IGF-I) plasma values, tumor size, and clinical outcome in patients with GH-secreting pituitary adenomas. "
8.	Sirolimus (Rapamycin)FDA Link 09/01/2009 - "The objective of the study was to evaluate the anti-proliferative efficacy of the mTOR inhibitor, rapamycin, and its orally bioavailable analog RAD001 on the GH-secreting pituitary tumor GH3 and MtT/S cells and in human GH-secreting pituitary adenomas (GH-omas) in primary cell cultures. "
9.	everolimus FDA Link 09/01/2009 - "The objective of the study was to evaluate the anti-proliferative efficacy of the mTOR inhibitor, rapamycin, and its orally bioavailable analog RAD001 on the GH-secreting pituitary tumor GH3 and MtT/S cells and in human GH-secreting pituitary adenomas (GH-omas) in primary cell cultures. "
10.	pasireotideIBA 04/01/2004 - "The higher number of responders of GH-secreting pituitary adenoma cultures to SOM230, compared with OCT, suggest that SOM230 has the potency to increase the number of acromegalic patients which can be biochemically controlled. " 04/01/2004 - "OCT (10 nM) significantly inhibited GH release in seven of nine GH-secreting pituitary adenoma cultures (range, -26 to -73%), SOM230 (10 nM) in eight of nine cultures (range, -22 to -68%), and SRIF-14 (10 nM) in six of six cultures (range, -30 to -75%). " 06/01/2010 - "Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide. " 01/01/2006 - "We report the comparative efficacy of octreotide, cabergoline and multiple ligands directed towards the different somatostatin subtypes (ssts), such as BIM-23A779 and SOM-230, and of chimeric analogs which bind both somatostatin and the dopamine D2 receptors (D2R), such as BIM-23A760 and BIM-23A781, in cell cultures from human growth hormone (GH)-secreting pituitary adenomas. "

Therapies and Procedures

1.	Radiotherapy 02/01/2005 - "The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas." 07/01/2008 - "The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma." 01/01/1998 - "Between 1983 and 1991, 21 patients suffering from GH-secreting pituitary adenomas were treated with radiotherapy alone. " 08/01/1996 - "Despite modern neurosurgical techniques for resecting GH-secreting pituitary adenomas, more than 50% of patients may have persistent GH hypersecretion; radiotherapy may take years to produce an effect. " 09/01/1993 - "Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma."
2.	Conformal Radiotherapy 07/15/2004 - "Stereotactic conformal radiotherapy is effective and safe in the treatment of GH-secreting pituitary adenoma to reduce hormonal overproduction and to improve local control. " 07/15/2004 - "Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma." 07/15/2004 - "To evaluate the reduction of hormonal overproduction and side effects as well as survival rates after fractionated stereotactic conformal radiotherapy (FSRT) and radiosurgery in patients with growth hormone (GH)-secreting pituitary adenoma. "
3.	Hypophysectomy 05/01/2010 - "This is the first report detailing transsphenoidal hypophysectomy as a feasible and effective treatment for feline acromegaly due to a pituitary somatotroph adenoma. "
4.	Aftercare (After-Treatment) 01/01/2007 - "A 68-year-old woman presented with persistent acromegaly after treatment for a GH-secreting pituitary adenoma. " 05/01/1998 - "Ten patients with GH-secreting pituitary adenoma were studied before and 6 months after treatment with subcutaneous octreotide 0.2 to 0.6 mg/day. " 01/01/2007 - "Our aim was to investigate whether patients with documented GH-secreting pituitary adenomas leading to acromegaly would respond with attenuation of GH and insulin-like growth factor-1 (IGF-1) levels after treatment with a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. "
5.	Therapeutics 10/01/2004 - "Despite important advances in human therapeutics, no specific treatment for both non-functioning gonadotroph and resistant somatotroph adenomas is available. "